CYP19A1 and breast cancer: We believe that Ki67 index value is sufficiently informative to guide clinical decision making for patients with hormone receptor‐positive breast cancer, because triaging breast cancer patients to neoadjuvant chemotherapy on the basis of Ki67 index >10% after neoadjuvant aromatase inhibitor treatment has been shown to be feasible.32